MabVax begins dosing of MVT-1075 in Phase I cancer therapy trial

US-based biotechnology firm MabVax Therapeutics has started dosing patients in a Phase I clinical trial of MVT-1075 to treat patients with CA19-9 positive malignancies such as pancreatic, colon and lung cancers.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news